Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid. If approved, Dupixent would be the first and only targeted medicine to treat BP in ...
(NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback